Haploidentical Hematopoietic Stem Cell Transplantation in the Treatment of Hematological Malignancies Using CAMPATH-1H
Haploidentical hematopoietic stem cell transplantation is a very important therapeutic
intervention for treatment of some genetic disorders and hematological malignancies.
In the majority of cases, there is no matched related or unrelated donor. Haploidentical
hematopoietic stem cell transplantation is a promising alternative for critical cases.
To avoid severe graft versus host disease (GVHD), two types of T cell depletion (TCD) had
been used: total TCD and partial TCD.
Total TCD has disadvantages such as increased rate of rejection and relapse, and increased
rate of infections due to delayed immune reconstitution.
Partial TCD has been done by in vivo and/or in vitro methods. In haploidentical
transplantation, donor partial TCD (ex vivo TCD) without recipient TCD increases the rate of
rejection and can not prevent severe GVHD successfully.
In vivo TCD by partial depletion of donor and recipient T cells has been done in
haploidentical transplantation with good results (to some extent inferior to full matched
transplantations) by using CAMPATH, ATG, etc.
Most of these studies have been performed in Chinese and Japanese populations that have more
homogenous genetic background than other populations.
In order to study the feasibility of this kind of transplantation in Iranian patients, we
defined a project to perform haploidentical hematopoietic stem cell transplantation by
using in vivo CAMPATH-1H.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Engraftment one month after transplantation
Up to 30 days from transplantation
Mohammadreza Ostadali, MD, Ph.D.
Hematology-Oncology & BMT Research Center
Iran: Ministry of Health